Follow The Filings

DRMA Dermata Therapeutics

Dermata Therapeutics earnings company data as of 4:48 AM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 13 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by DRMA's executives, directors and 10% owners in the last 12 months, from their Form 4s

All DRMA insider trades
  • $1,270 bought by 1 insider
  • $13 sold by 1 insider outside a trading plan
  • None no planned (10b5-1) sales
  1. Kathleen D. Scott Director
    Sale
    $13 11 shares at $1.19 100% of stake
    Traded Jun 16 Filed Jun 16
    ↗
  2. Munera Maria E Bedoya-Toro SVP, Regulatory Affairs
    Buy
    $1,270 1,000 shares at $1.27 +8333% to stake
    Traded Feb 17 Filed Mar 17
    ↗

Also filed in the last 12 months, not counted as buying or selling: 5 stock grants.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
424B3 Filing Doc
8-K 1.01,3.02,8.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 8.01 Filing Doc
SCHEDULE 13D — Filing Doc
424B3 Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
8-K 5.02 Filing Doc
SCHEDULE 13D/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 4.01,9.01 Filing Doc
SCHEDULE 13D/A — Filing Doc
424B3 Filing Doc
424B5 Filing Doc

Source: SEC EDGAR submissions, updated 2 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.